Myriad Genetics, Inc. (MYD.F)

22,20 +2,70 (+13,85%) Ab 08:00AM CEST. Markt geöffnet.

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 2.700

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Paul J. Diaz	CEO, President & Director	2,15M	N/A	1962
Mr. Samraat S. Raha	Chief Operating Officer	478,85k	N/A	1973
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer	759,54k	N/A	1980
Mr. Mark S. Verratti	Chief Commercial Officer	851,91k	N/A	1968
Mr. Scott J. Leffler	Chief Financial Officer	N/A	N/A	1975
Ms. Natalie Munk	Principal Accounting Officer	N/A	N/A	1981
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer	539,87k	N/A	1986
Mr. Matthew Scalo	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer	N/A	N/A	N/A
Ms. Shereen Solaiman	Chief People Officer	N/A	N/A	1973

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Myriad Genetics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 10, Vorstand: 1, Shareholderrechte: 5, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.